OncoMatch/Clinical Trials/NCT05180097
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Is NCT05180097 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for hodgkin lymphoma.
Treatment: Gemcitabine · Dexamethasone · Cisplatin · Brentuximab vedotin · Pembrolizumab — This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Hodgkin Lymphoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anthracycline-containing chemotherapy
relapsed or refractory disease after anthracycline-containing chemotherapy
Cannot have received: salvage systemic therapy
Participants who have received prior salvage systemic therapy for their relapsed or refractory disease.
Lab requirements
Blood counts
absolute neutrophils ≥1.0 x 10^9/l; platelets ≥75 x 10^9/l; hemoglobin ≥80 g/l
Kidney function
serum creatinine <1.55 x unl or creatinine clearance ≥30 ml/min
Liver function
bilirubin ≤1.50 x unl; ast and alt ≤2.50 x unl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05180097 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior salvage systemic therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages